April 22, 2024

Festival of Biologics 2026

Festival of Biologics 2026
Go back

About Festival of Biologics

The Festival of Biologics Basel is Europe’s largest biologics event, covering the start-to-finish of the industry in antibody therapies, cell and gene therapies, immunotherapies and biosimilars. Designed for industry experts in pharma and biotech, start-ups, academics, regulators and investors, the Festival of Biologics is the meeting place for the large molecule therapy ecosystem, bringing together 3000+ attendees.
Join 350 world class speakers in exploring the latest research in early stage discovery, modality engineering, translational medicine, clinical trials, manufacturing, commercialisation and fill/finish operations across key therapy and disease areas. With three days of presentations, panels, roundtables and workshops, this event is the place to be to keep up with the latest advances across the entire biologics and ATMP value chain.

BioRN members receive a 20 % discount.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.

register now

Our latest News

discover more
Study shows how lymph node architecture affects cancer growth

Study shows how lymph node architecture affects cancer growth

A new study maps the organisation of immune and stromal cells in lymph nodes and shows how loss of this organisation affects prognosis in certain lymphomas Summary Researchers from EMBL Heidelberg, Heinrich Heine University Düsseldorf (HHU), and Düsseldorf University Hospital (UKD) have succeeded for the first time in mapping the organisation of immune and stromal […]

read more
High-throughput testing of drugs on mini-tumors reveals vulnerabilities in meningiomas

High-throughput testing of drugs on mini-tumors reveals vulnerabilities in meningiomas

Meningiomas are the most common brain tumors. Until now, only two methods have generally been considered for treating them: surgery and radiation therapy. A research team in Heidelberg has now developed a potential new approach for effective systemic therapy. Its members from Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital (UKHD) tested the effectiveness […]

read more
Development of a method for improved monitoring of the early stages of bone marrow cancer

Development of a method for improved monitoring of the early stages of bone marrow cancer

An international team, including researchers from Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital, has developed the PANGEA-SMM prognostic tool. This tool makes it possible to determine with greater accuracy than before whether a precancerous condition—known as “smoldering multiple myeloma”—is progressing and thus requires treatment. The free online tool for treatment teams is available […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp